Oral antiviral drugs
Pro Research Analysisby 
Searched over 200M research papers
Oral Antiviral Drugs: Efficacy, Safety, and Applications
COVID-19 Oral Antiviral Drugs: Molnupiravir, Fluvoxamine, and Paxlovid
Recent studies have highlighted the efficacy and safety of three novel oral antiviral drugs—molnupiravir, fluvoxamine, and Paxlovid—in treating COVID-19. A meta-analysis involving 4,788 COVID-19 patients demonstrated that these drugs significantly reduced mortality and hospitalization rates by approximately 67% compared to placebo groups . Importantly, these drugs did not increase the occurrence of adverse events, indicating a favorable safety profile . This suggests that these oral antivirals could be a promising breakthrough in the ongoing fight against COVID-19.
Oral Direct-Acting Antivirals for Hepatitis C Virus (HCV)
Oral direct-acting antiviral (DAA) regimens have revolutionized the treatment of chronic HCV infection. A systematic review of 42 studies revealed that multiple DAA regimens achieve high sustained virologic response (SVR) rates (>95%) in patients with HCV genotype 1 infection, including those co-infected with HIV . However, the efficacy is somewhat lower in patients with hepatic decompensation and those with HCV genotype 3 infection . The addition of ribavirin to certain DAA regimens can enhance SVR rates, although it may also increase the incidence of mild to moderate adverse events .
Oral Antivirals for Herpes Zoster
Oral antiviral agents such as acyclovir, valacyclovir, and famciclovir are crucial in the treatment of herpes zoster. These drugs significantly reduce the duration and intensity of zoster-associated pain (ZAP) when administered within 72 hours of symptom onset . Valacyclovir and famciclovir offer better oral bioavailability and require less frequent dosing compared to acyclovir, making them more convenient for patients . These agents are also beneficial for immunocompromised patients, although intravenous therapy may be necessary if there are signs of cutaneous or visceral dissemination .
Preventing Mother-to-Child Transmission of Hepatitis B Virus (HBV)
Oral antiviral drugs such as lamivudine, telbivudine, and tenofovir are effective in reducing mother-to-child transmission (MTCT) of HBV. A network meta-analysis involving 12,740 pregnant women found that tenofovir was the most effective, significantly decreasing MTCT rates compared to lamivudine and telbivudine . These findings underscore the importance of antiviral therapy in highly viremic mothers to prevent HBV transmission to their newborns .
Broad-Spectrum Oral Antiviral CMX001
CMX001, a novel lipid antiviral conjugate, has shown promise as a broad-spectrum oral antiviral agent. In a dose-escalating study, CMX001 was well tolerated in healthy volunteers, with no significant adverse events or gastrointestinal mucosal changes observed . The drug demonstrated rapid absorption and favorable pharmacokinetic properties, suggesting its potential efficacy against multiple double-stranded DNA viruses .
Nitazoxanide: Amplifying Host Antiviral Responses
Nitazoxanide (NTZ), an FDA-approved oral drug, has been found to enhance host innate immune responses and inhibit Ebola virus (EBOV) replication. NTZ amplifies the activity of key antiviral proteins and significantly inhibits EBOV replication in human cells . This broad-spectrum antiviral activity suggests that NTZ could be a valuable oral therapy against various viral infections, including EBOV .
Favipiravir-Based Ionic Liquids for COVID-19
Favipiravir (FAV) is an antiviral drug currently under investigation for COVID-19 treatment. Researchers have developed favipiravir-based ionic liquids (FAV-ILs) to improve its solubility and bioavailability. These FAV-ILs exhibited significantly enhanced solubility and pharmacokinetic properties, leading to better drug absorption and distribution in the lungs and liver . This innovative approach could enhance the therapeutic efficacy of favipiravir for COVID-19 .
Conclusion
Oral antiviral drugs have shown significant promise across various viral infections, including COVID-19, HCV, herpes zoster, and HBV. The development and optimization of these drugs continue to provide new hope for effective and convenient treatments, improving patient outcomes and public health.
Sources and full results
Most relevant research papers on this topic
Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection
Multiple oral DAA regimens show high rates of safety, tolerability, and efficacy for treating HCV genotype 1 infection, particularly among individuals without cirrhosis.
Oral Antivirals Revisited in the Treatment of Herpes Zoster
Oral antivirals, particularly acyclovir, effectively reduce herpes zoster-related symptoms and pain, with potential benefits for elderly immunocompetent patients and immunocompromised patients.
Antiviral Agents for the Prevention and Treatment of Herpes Simplex Virus Type-1 Infection in Clinical Oncology: A Network Meta-Analysis
Acyclovir and valacyclovir are the best antiviral agents for preventing oral herpes simplex virus infection in cancer patients, with 750 mg/m2 intravenously followed by 1600 mg per day orally being the most effective regimens.
The FDA-Approved Oral Drug Nitazoxanide Amplifies Host Antiviral Responses and Inhibits Ebola Virus
Nitazoxanide (NTZ) effectively amplifies the host innate immune response to viruses and inhibits Ebola virus replication, offering potential as an oral therapy against EBOV.
Molnupiravir and Nirmatrelvir-Ritonavir: Oral COVID Antiviral Drugs
Nirmatrelvir-ritonavir shows a greater risk reduction in hospitalization and death than molnupiravir for mild to moderate COVID-19 patients, but both drugs must be started within five days of symptoms onset.
DOI